Marco Marzioni1, Chiara Bassanelli2, Claudio Ripellino3, Duccio Urbinati3, Domenico Alvaro4. 1. Clinic of Gastroenterology and Hepatology, Università Politecnica delle Marche, Via Tronto 10/A 60126, Ancona, Italy. 2. Intercept Italia srl, Via Giosuè Carducci 24, 20123, Milan, Italy. 3. IQVIA, Via Fabio Filzi 29 20124, Milan, Italy. 4. Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Viale del Policlinico 155, 00185, Rome, Italy. Electronic address: domenico.alvaro@uniroma1.it.
Abstract
BACKGROUND: Primary biliary cholangitis is an autoimmune disease affecting the interlobular bile ducts. Limited information is available on its epidemiology and treatment in Italy. AIMS: To describe primary biliary cholangitis epidemiology and investigate treatment patterns for Italian patients with this disease. METHODS: Electronic medical records from 900 general practitioners (part of the QuintilesIMS™ Longitudinal Patient Databases) were examined. Demographics were compared with those from the Italian National Institute of Statistics dataset. The International Classification of Diseases, Ninth Revision, biliary cirrhosis code 571.6 was used for diagnosis, and data on comorbidities, concomitant medications, medical examinations, specialist referrals, and treatments were collected. RESULTS: This dataset was representative of the Italian population. Point prevalence of primary biliary cholangitis was calculated as 27.90 per 100,000 and incidence as 5.31 per 100,000 inhabitants/year. Some associations between the disease and comorbidities were sex specific. The most common laboratory assays requested were for liver enzymes, and the majority of patients were not referred to a specialist. Ursodeoxycholic acid was the most common therapy. CONCLUSION: This can be used as a benchmark for monitoring and identifying unmet needs to improve treatment in Italy.
BACKGROUND:Primary biliary cholangitis is an autoimmune disease affecting the interlobular bile ducts. Limited information is available on its epidemiology and treatment in Italy. AIMS: To describe primary biliary cholangitis epidemiology and investigate treatment patterns for Italian patients with this disease. METHODS: Electronic medical records from 900 general practitioners (part of the QuintilesIMS™ Longitudinal Patient Databases) were examined. Demographics were compared with those from the Italian National Institute of Statistics dataset. The International Classification of Diseases, Ninth Revision, biliary cirrhosis code 571.6 was used for diagnosis, and data on comorbidities, concomitant medications, medical examinations, specialist referrals, and treatments were collected. RESULTS: This dataset was representative of the Italian population. Point prevalence of primary biliary cholangitis was calculated as 27.90 per 100,000 and incidence as 5.31 per 100,000 inhabitants/year. Some associations between the disease and comorbidities were sex specific. The most common laboratory assays requested were for liver enzymes, and the majority of patients were not referred to a specialist. Ursodeoxycholic acid was the most common therapy. CONCLUSION: This can be used as a benchmark for monitoring and identifying unmet needs to improve treatment in Italy.